


Statement of Standalone Unaudited Financial Results for the Quarter and Half Year Ended 30th September, 2018

Rs. in Lakhs

Sr. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2018 (Unaudited)	30.06.2018 (Unaudited)	30.09.2017 (Unaudited)	30.09.2018 (Unaudited)	30.09.2017 (Unaudited)	31.03.2018 (Audited)
1	Revenue from Operations	3,356	4,452	3,254	7,808	6,215	12,530
2	Other Income	2,422	130	2,597	2,552	2,983	3,701
3	Total Income	5,778	4,582	5,852	10,360	9,198	16,231
4	Expenses						
	Cost of Materials Consumed	1,806	546	1,126	2,352	1,745	3,986
	Cost of Construction	400	1,427	769	1,827	1,410	3,078
	Changes in Inventories of Finished Goods and WIP	(596)	766	154	170	899	809
	Employee Benefit Expenses	662	485	515	1,147	1,008	2,074
	Finance Costs	4	6	7	11	11	17
	Depreciation and amortisation expense	56	64	112	120	236	378
	Other Expenses	449	403	192	852	477	1,472
	Total Expenses	2,782	3,697	2,875	6,479	5,786	11,813
5	Profit Before Tax	2,996	885	2,976	3,881	3,412	4,417
6	Tax Expenses						
	Current Tax	147	190	137	337	227	431
	Deferred Tax	(86)	20	17	(67)	28	30
	Short / (Excess) Provision of earlier years	-	(16)	-	(16)	-	(222)
7	Net Profit after tax for the Period	2,935	691	2,822	3,627	3,157	4,178
8	Other Comprehensive Income						
	(i) Items that will not be reclassified to Profit or Loss	3,368	942	521	4,311	526	4,443
	(ii) Income tax relating to items that will not be reclassified to Profit or Loss	160	(134)	(180)	27	(183)	114
9	Total Comprehensive Income for the Period	6,464	1,500	3,163	7,964	3,500	8,735
10	Earnings per equity share (FV Rs. 2/- per share) Basic & Diluted (In Rs.)	1.14	0.26	1.06	1.40	1.18	1.56



Alembic Limited
Segment wise Standalone Revenue and Results

Rs. In Lakhs


Sr. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2018 (Unaudited)	30.06.2018 (Unaudited)	30.09.2017 (Unaudited)	30.09.2018 (Unaudited)	30.09.2017 (Unaudited)	31.03.2018 (Audited)
1	Segment Revenue						
	Revenue from Operations						
	a. Active Pharmaceutical Ingredients Business	1,865	1,955	1,776	3,819	3,519	6,636
	b. Real Estate Business	1,491	2,498	1,479	3,989	2,696	5,893
	Total Income from Operations (Net)	3,356	4,452	3,254	7,808	6,215	12,530
2	Segment Results (Profit (+)/ Loss (-) before Taxes and interest from each segment)						
	a. Active Pharmaceutical Ingredients Business	21	99	139	119	144	26
	b. Real Estate Business	653	727	354	1,380	517	1,319
	Total	674	826	494	1,500	661	1,346
	Unallocable Income and Expenditure						
	(i) Interest Expense	(4)	(6)	(7)	(11)	(11)	(17)
	(ii) Dividend Income and Gain on financial asset at Fair Value	2,293	33	2,503	2,327	2,738	2,940
	(iii) Other Income / (Expense)	33	32	(13)	65	24	148
	Total Profit Before Tax	2,996	885	2,976	3,881	3,412	4,417
3	Segment Assets						
	a. Active Pharmaceutical Ingredients Business	18,020	17,456	18,887	18,020	18,887	17,189
	b. Real Estate Business	8,708	9,294	7,295	8,708	7,295	7,426
	c. Unallocated	25,723	19,722	21,338	25,723	21,338	27,581
	Total	52,451	46,473	47,520	52,451	47,520	52,196
4	Segment Liabilities						
	a. Active Pharmaceutical Ingredients Business	3,222	2,457	2,180	3,222	2,180	2,071
	b. Real Estate Business	4,274	4,575	4,195	4,274	4,195	4,309
	c. Unallocated	941	1,272	1,512	941	1,512	947
	Total	8,437	8,304	7,887	8,437	7,887	7,328

Notes:

- The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.
- The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.
- The Board of Directors of the Company in their meeting held on 3rd November, 2018 have considered and accorded approval to the Composite Scheme of Arrangement between Alembic Limited, Shreno Limited and Nirayu Private Limited and their respective shareholders under section 230-232 of the Companies Act, 2013 and the rules and regulations made thereunder ("Scheme"), involving, inter alia, merger of the Identified Real Estate Undertaking (as defined in the Scheme) of the Company into Shreno Limited w.e.f 1st November 2018, being the Appointed Date.

For Alembic Limited

Place : Vadodara
Date : 3rd November, 2018



[Signature]
Nirayu Amin
Chairman

Alembic Limited


Statement of Standalone Assets and Liabilities

Rs. in Lakhs

Particulars	As at 30th Sept, 2018	As at 31st March, 2018
	Unaudited	Audited
ASSETS		
Non-Current Assets		
(a) Property, Plant and Equipment	13,165	13,223
(b) Investment Property	6,493	4,681
(c) Financial Assets		
(i) Investments	19,751	15,596
(ii) Loans	9	27
	39,419	33,527
Current Assets		
(a) Inventories	2,872	3,241
(b) Financial Assets		
(i) Investments	5,971	11,985
(ii) Trade Receivables	2,995	2,529
(iii) Cash and Cash Equivalents	134	44
(iv) Bank Balances other than (iii) above	47	37
(v) Loans	8	-
(vi) Others	2	124
(c) Other Current Assets	881	576
(d) Assets held for sale	121	132
	13,032	18,669
TOTAL - ASSETS	52,451	52,196
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share Capital	5,136	5,341
(b) Other Equity	38,878	39,528
	44,013	44,869
Liabilities		
Non-Current Liabilities		
(a) Financial Liabilities		
(i) Other Financial Liabilities	457	412
(b) Provisions	607	80
(c) Deferred Tax Liability (Net)	758	923
	1,822	1,415
Current Liabilities		
(a) Financial Liabilities		
(i) Trade Payables		
a) Due to Micro and Small Enterprises	-	-
b) Due to other than Micro and Small Enterprises	2,954	1,642
(ii) Other Financial Liabilities	1,290	1,495
(b) Other Current Liabilities	1,116	1,686
(c) Provisions	1,073	1,065
(d) Current Tax Liabilities (Net)	183	24
	6,615	5,912
TOTAL - EQUITY AND LIABILITIES	52,451	52,196

For Alembic Limited

Place : Vadodara
Date : 3rd November, 2018



Chirayu Amin
Chirayu Amin
Chairman

Limited Review Report**To the Board of Directors of Alembic Limited**

1. We have reviewed the accompanying statement of unaudited standalone Ind-AS financial results of **Alembic Limited** ("the Company") for the quarter/half year ended 30th September, 2018 ("the Statement") together with the notes thereon attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which has been initialed by us for identification purposes.
2. This Statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.
4. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited standalone Ind-AS financial results has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, **C N K & Associates LLP**

Chartered Accountants

Firm Registration no. 101961W/W-100036

**Alok B Shah**

(Partner)

Membership No. 042005

Vadodara, 3rd November, 2018

